BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 3024851)

  • 1. Cytoxan, epirubicin, methotrexate and 5-fluorouracil with hormonal synchronization (tamoxifen/premarin) in advanced breast cancer. Preliminary results.
    Zaniboni A; Simoncini E; Marpicati P; Gorni F; Cervi GC; Marini G
    Chemioterapia; 1986 Oct; 5(5):341-6. PubMed ID: 3024851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of locally advanced breast cancer using primary induction chemotherapy with hormonal synchronization followed by radiation therapy with or without debulking surgery.
    Lippman ME; Sorace RA; Bagley CS; Danforth DW; Lichter A; Wesley MN
    NCI Monogr; 1986; (1):153-9. PubMed ID: 3022156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tamoxifen and conjugated estrogens (Premarin) followed by sequenced methotrexate and 5-FU in refractory advanced breast cancer.
    Eisenhauer EA; Bowman DM; Pritchard KI; Paterson AH; Ragaz J; Plenderleith I; Geggie PH; Maxwell I
    Cancer Treat Rep; 1984 Nov; 68(11):1421-2. PubMed ID: 6094005
    [No Abstract]   [Full Text] [Related]  

  • 4. Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer.
    Swain SM; Sorace RA; Bagley CS; Danforth DN; Bader J; Wesley MN; Steinberg SM; Lippman ME
    Cancer Res; 1987 Jul; 47(14):3889-94. PubMed ID: 3036348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
    Bottini A; Berruti A; Bersiga A; Brizzi MP; Brunelli A; Gorzegno G; DiMarco B; Aguggini S; Bolsi G; Cirillo F; Filippini L; Betri E; Bertoli G; Alquati P; Dogliotti L
    Clin Cancer Res; 2000 Jul; 6(7):2751-8. PubMed ID: 10914720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclophosphamide, methotrexate, and chronic oral tegafur modulated by folinic acid in the treatment of patients with advanced breast carcinoma.
    Ribas A; Albanell J; Solé-Calvo LA; Gallardo E; Bellmunt J; Vera R; Vidal R; Carulla J; Baselga J
    Cancer; 1998 Mar; 82(5):878-85. PubMed ID: 9486577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy and concomitant irradiation in inflammatory breast cancer.
    Tubiana-Mathieu N; Lejeune C; Bonnier P; Genet D; Adjadj DJ; Berda JF; Muracciole X; Delaby F; Clavere P; Benyoub A; Rhein B; Juin B; Piana L
    Anticancer Res; 2001; 21(4B):3061-7. PubMed ID: 11712811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methotrexate, mitoxantrone, 5-fluorouracil and leucovorin in metastatic breast cancer patients.
    Merlini L; Secondo V; Mammoliti S; Bellotti P; Castello C; Gallo L
    Anticancer Res; 1994; 14(3B):1423-6. PubMed ID: 8067717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy.
    Foekens JA; Romain S; Look MP; Martin PM; Klijn JG
    Cancer Res; 2001 Feb; 61(4):1421-5. PubMed ID: 11245445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized attempt to increase the efficacy of cytotoxic chemotherapy in metastatic breast cancer by hormonal synchronization.
    Lippman ME; Cassidy J; Wesley M; Young RC
    J Clin Oncol; 1984 Jan; 2(1):28-36. PubMed ID: 6321686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes.
    Battelli N; Massacesi C; Braconi C; Pilone A; Manzione L; Dinota A; Cobelli S; Scanni A; Sturba F; Giacomini G; Morale D; Giorgi F; Tummarello D; Cascinu S
    Am J Clin Oncol; 2006 Aug; 29(4):380-4. PubMed ID: 16891866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
    Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
    Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclophosphamide, epirubicin and cisplatin (CEP) in advanced breast cancer: preliminary results.
    Zaniboni A; Marpicati P; Simoncini E; Gorni F; Ferrari V; Raffaglio E; Garattini MP; Marini G
    Anticancer Res; 1987; 7(4B):813-5. PubMed ID: 3479042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102.
    Hutchins LF; Green SJ; Ravdin PM; Lew D; Martino S; Abeloff M; Lyss AP; Allred C; Rivkin SE; Osborne CK
    J Clin Oncol; 2005 Nov; 23(33):8313-21. PubMed ID: 16293862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
    Cocconi G; Di Blasio B; Boni C; Bisagni G; Ceci G; Rondini E; Bella M; Leonardi F; Savoldi L; Camisa R; Bruzzi P
    Cancer; 2002 Jul; 95(2):228-35. PubMed ID: 12124820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [High-dose CEF (cyclophosphamide, epirubicin, fluorouracil) as primary chemotherapy in locally advanced breast cancer: long-term results].
    Conti F; Carpano S; Sergi D; Di Lauro L; Amodio A; Vici P; Abbate MI; Ferranti FR; Viola G; Botti C; Foggi P; Sperduti I; Lopez M
    Clin Ter; 2007; 158(4):331-41. PubMed ID: 17953285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidoxorubicin and paclitaxel as primary chemotherapy for T > 3 cm and T4 breast cancer patients.
    Bellino R; Cortese P; Danese S; De Sanctis C; Durando A; Genta F; Grio R; Giardina G; Katsaros D; Massobrio M; Richiardi G; Vicelli R
    Anticancer Res; 2000; 20(6C):4825-8. PubMed ID: 11205227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of the therapeutic effect of CMxMF and CAMF regimens in the management of advanced breast cancer patients].
    Chen JA
    Zhonghua Zhong Liu Za Zhi; 1993 May; 15(3):202-4. PubMed ID: 8261866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
    Ryberg M; Nielsen D; Cortese G; Nielsen G; Skovsgaard T; Andersen PK
    J Natl Cancer Inst; 2008 Aug; 100(15):1058-67. PubMed ID: 18664656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant chemotherapy for Chinese women with locally advanced breast cancer.
    Chow LW; Day W; Ng KC
    Am Surg; 2001 May; 67(5):412-6. PubMed ID: 11379638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.